



Funding and procurement mechanisms for SARS-COV-2 antigen rapid tests

ASLM WEBINAR 27 OCTOBER 2020

The Global Fund is providing up to US\$1 billion and operational flexibility to help countries fight COVID-19, shore up health systems and mitigate the impacts on lifesaving HIV, TB and malaria programs.

COVID-19 Response Mechanism

- Countries can access funding to reinforce the response to COVID-19, mitigate the impact of the pandemic on HIV, TB and malaria programs, and make urgent improvements in health and community systems.

Grant flexibilities

- Countries can use up to 5% of existing Global Fund grants to fight COVID-19 and mitigate the impact the pandemic has on HIV, TB and malaria programs.



<https://www.theglobalfund.org/en/covid-19/>


Overview

The Global Fund's response to the COVID-19 pandemic makes funding available through the COVID-19 Response Mechanism and grant flexibilities. This report lists approved funding.

Learn more at <https://www.theglobalfund.org/en/covid-19/>

Total approved in USD equivalent	808,586,498
Total countries and multiculties	120

Countries Accessing Global Fund Support to Fight COVID-19



COVID-19 Response Mechanism

Last updated : 26 Oct 2020

	USD equivalent
Total mitigating COVID-19 impact on HIV, TB and malaria programs	197,159,540
Total reinforcing national COVID-19 response (Other response)	211,022,639
Total reinforcing national COVID-19 response (COVID-19 diagnostic tests)	116,777,286
Total urgent improvements in health and community systems	67,534,275
Total immediate funding	592,493,744

Country/Multicountry	Currency	Mitigating COVID-19 impact on HIV, TB and malaria	Reinforcing national COVID-19 response		Urgent improvements in health and	Total immediate funding
			Other response	COVID-19 diagnostic tests		
Afghanistan	USD	2,381,174	954,826		1,004,623	4,340,623
Albania	USD	29,972	24,485	103,040		157,497
Angola	USD	1,957,716	299,428	2,698,877		4,956,021
Armenia	USD	375,100	200,750	275,498		851,348
Azerbaijan	USD	1,107,834				1,107,834
Bangladesh	USD	1,148,176	2,710,892	1,434,882	2,227,979	7,521,929
Belarus	USD	487,435	491,600	141,360	75,530	1,195,925
Belize	USD	25,355	32,722	92,030	78,223	228,330
Benin	USD	2,835,372	1,278,684		2,243,986	6,358,042
Bhutan	USD	157,859		18,600		176,459
Bolivia (Plurinational State)	USD	943,233	86,318	134,000	229,684	1,393,235
Botswana	USD	811,749	266,295		152,833	1,230,877

Grant Flexibilities

Last updated : 16 Oct 2020

Total USD approved	216,092,754
Total countries and multiculties	107

Country/Multicountry	USD equivalent
Afghanistan	993,696
Albania	80,400
Algeria	226,249
Angola	1,581,988
Armenia	115,370
Azerbaijan	119,040
Bangladesh	8,180,249
Belarus	644,251
Belize	27,622
Benin	392,770

EXAMPLES OF ACTIVITIES FUNDED BY C19RM

- **Procuring COVID-19 Diagnostic Tests,**
- **Purchasing PPE,**
- Scaling up investments for **oxygen equipment and therapy.**
- **Reinforcing treatment and care for TB, HIV and malaria,**
- Providing **nutrition support** for the most vulnerable and severely malnourished TB and HIV patients.
- **Strengthening laboratory capacity**
- **Scaling up testing** across the three diseases,
- Supporting interventions aimed at **AGYW, GBV, Human Rights and KP outreach**, including community capacity building and support.
- Supporting the **training of health care workers.**
- Supporting **communication and sensitization activities.**

SUPPLY & PROCUREMENT OF HEALTH PRODUCTS

The screenshot shows the 'COVID-19' section of The Global Fund's website. The main navigation bar includes 'OUR PARTNERSHIP', 'FUNDING & IMPLEMENTATION', 'NEWS & STORIES', and 'RESOURCE LIBRARY'. The page title is 'COVID-19' and the sub-header is 'Health Product Supply'. The left sidebar contains a menu with items like 'Overview', 'Situation Reports & News', 'Response Mechanism', 'Grant Funding & Flexibilities', 'Technical Guidance', 'Health Product Supply', 'Updates', 'Diagnostics', 'Personal Protective Equipment and Oxygen', 'Procurement Advice', 'Quality Assurance', 'Access to COVID-19 Tools Accelerator', 'Our Perspective', and 'Share this page'. The main content area features a section titled 'Health Product Supply' with an introductory paragraph, a highlighted box containing an assessment as of 12 October 2020, and a list of documents including 'COVID-19 Impact on Health Product Supply: Assessment and Recommendations' and 'Diagnostics'.

COVID-19 [Latest Information](#)

The Global Fund OUR PARTNERSHIP FUNDING & IMPLEMENTATION NEWS & STORIES RESOURCE LIBRARY English | Français

COVID-19

- Overview
- Situation Reports & News**
- Response Mechanism
- Grant Funding & Flexibilities
- Technical Guidance
- Health Product Supply**
 - Updates
 - Diagnostics**
 - Personal Protective Equipment and Oxygen
 - Procurement Advice
 - Quality Assurance
- Access to COVID-19 Tools Accelerator
- Our Perspective
- Share this page

Health Product Supply

The COVID-19 pandemic has far-reaching impacts on global health product supply chains. The Global Fund works closely with suppliers, implementers and partners to assess the impact on core health product supplies for Global Fund grants. We provide recommendations for implementers on how to manage this impact and offer channels to ensure the continued flow of quality-assured health products through:

Assessment and recommendations

As of 12 October 2020, the Global Fund's product and delivery outlook shows the overall impact of COVID-19 on health product supply chains for Global Fund grants remains at **moderate**.

The Global Fund's health product supply response to the pandemic includes regular category-by-category operational risk assessments, recommendations for implementers and other actions. Our document details our latest assessment and recommendations:

- COVID-19 Impact on Health Product Supply: Assessment and Recommendations
[download in English](#)

Health products are a critical component of a country's effective emergency response to COVID-19. Countries can access support to secure products through [grant flexibilities](#) and the COVID-19 Response Mechanism. Our documents and pages detail procuring:

- Diagnostics

- Overview
- Situation Reports & News
- Response Mechanism
- Grant Funding & Flexibilities
- Technical Guidance
- Health Product Supply**
 - Updates
 - Diagnostics**
 - Personal Protective Equipment and Oxygen
 - Procurement Advice
 - Quality Assurance
- Access to COVID-19 Tools Accelerator
- Our Perspective

[View Related Resources](#)

- Share this page
- Twitter Facebook
- Print

Diagnostics

The Global Fund is working closely with key partners, international organizations, governments and technical agencies through a World Health Organization led consortium to rapidly and equitably support access to COVID-19 health products and diagnostics for low- and middle-income countries.

Read our questions and answers document for the latest information on procuring the diagnostics:

- [Ordering COVID-19 Diagnostics through the Global Fund: Frequently Asked Questions](#) [download in Portuguese](#) | [Español](#) | [Français](#) | [English](#)
- [PPM Reference Price List for COVID-19 Diagnostics](#) [download in English](#)

SARS-CoV-2 antigen-detecting rapid diagnostic test

Providing a COVID-19 test to all those who need it requires rapid expansion of diagnostic testing capacity. Facilitating access to testing is the priority of the ACT Accelerator Diagnostics Pillar, which is co-convened by the Global Fund. Antigen rapid diagnostics tests (Ag RDTs) that detect the presence of COVID-19 infection (SARS-CoV-2) that were released on the market in the initial stages were unreliable, but there are now two reader-free Ag RDTs which perform well. WHO published the interim guidance [Antigen Detection in the Diagnosis of SARS-CoV-2 Infection Using Rapid Immunoassays](#) on 11 September 2020.

In order to detect SARS-CoV-2, laboratories have been mainly using nucleic acid amplification tests (NAATs) such as real-time reverse transcription polymerase chain reaction (rRT-PCR) assays. While this method has been highly reliable, it also comes with a certain cost and time investment and many countries face challenges in access to this form of testing.

Ag RDTs therefore represent a significant step forward in reinforcing the effectiveness of COVID-19 response strategies because of their low cost of approximately US\$5 per test, turnaround of results within 30 minutes and without the need to rely on laboratory instruments.

Polymerase chain reaction (PCR) tests continue to play an essential role in the COVID-19 response strategy per WHO's guidance. The Global Fund encourages implementing countries to move swiftly and prepare to strategically deploy Ag RDTs as well.

Accessing the tests

The Global Fund will make SARS-CoV-2 Ag RDTs available for procurement to countries through its funding mechanisms when:

1. Countries have endorsed the use of these tests in their national COVID-19 testing strategies.
2. They are planned to be used as recommended in WHO guidance.
3. SARS-CoV-2 Ag RDTs meet the quality assurance requirements as per the current Global Fund quality assurance policy supplemented by the [Interim Quality Assurance Requirements for the Procurement of COVID-19 Diagnostic Products](#) [\[download in English\]](#).

For more information, see [COVID-19 Response Mechanism](#), [other grant flexibilities](#), [health product](#)

Available tests

The SD Biosensor Standard Q COVID-19 Ag Test and Abbott Panbio COVID-19 Ag Rapid Test Device are currently available for procurement and commercially available to low- and middle-income countries via the Global Fund's Pooled Procurement Mechanism. Principal Recipients who are not participating in the Global Fund's Pooled Procurement Mechanism should contact onboarding@wambo.org and their Country Team.

Governments and non-governmental organizations in Global Fund eligible and transitioned countries can also procure SARS-CoV-2 Ag RDTs tests using non-Global Fund sources of funding through wambo.org by contacting onboarding@wambo.org or through other procurement channels.

SARS-CoV-2 polymerase chain reaction

Following the initial allocation of diagnostics tests for COVID-19 (SARS-CoV-2 polymerase chain reaction) from major manufacturers to 140 countries for the May to August 2020 period, WHO has updated the test allocation for September 2020 to February 2021.

The allocation methodology calculates each country's minimum available volumes by taking each country's population and adjusting for both vulnerability and epidemiology to support countries with more fragile health systems and/or severe outbreaks, while factoring constraints due to monthly polymerase chain reaction (PCR) testing capacity, if applicable. The vulnerability adjustment is based on the WHO Universal Health Coverage Index and epidemiology is calculated from confirmed cases per population.

Test allocations

WHO has communicated the total volumes available through their country offices and are contained in the list:

- [Diagnostics Consortium Initial Allocation for Cepheid GeneXpert COVID-19 Polymerase Chain Reaction Tests](#) [download in English](#)

In addition, volumes of Abbott and Roche PCR Tests are available for procurement. More information on accessing these tests is provided in the [Frequently Asked Questions](#) [\[download in Portuguese](#) | [Español](#) | [Français](#) | [English](#)].

Accessing the tests

The WHO allocation model for September 2020 to February 2021 considers any test volumes



UNITE^{TO}FIGHT